Peter Hillmen P, Badoux X, Delgado J, et al. Safety results of terminated phase 2 study of idelalisib plus rituximab in treatment naïve chronic lymphocytic leukemia (CLL) with del(17p). EHA 2017, abstract S465.
Epcoritamab en tislelizumab in de sluis geplaatst
nov 2023 | Lymfoom, Maag-darm-leveroncologie